Table of contents
June 2005 Vol 4 No 6
In this issue
p441 | doi:10.1038/nrd1772
Editorial: The long and winding road
p443 | doi:10.1038/nrd1770
News and Analysis
New CEO appointment reveals Merck's response to setbacks | PDF (157 KB)
p445 | doi:10.1038/nrd1765
Why big pharma needs to learn the three 'R's | PDF (64 KB)
p446 | doi:10.1038/nrd1766
Flu virus lapses shows quantum leap in technologies needed | PDF (106 KB)
p447 | doi:10.1038/nrd0605
News in Brief
Anti-angiogenics steal the show | New FDA safety initiatives proposed | Monster diabetes drug approved | Good news for stroke drug? | European regulators review antidepressants in children | End of a genomics era | Debate over heart failure drug | US army says no to Nexium | Rebranding PhRMA | GSK boost for vaccines | PDF (213 KB)
p448 | doi:10.1038/nrd1768
Patent watch
Lilly holds onto Zyprexa patent | PDF (558 KB)
p450 | doi:10.1038/nrd1758
Patent watch
Merck and Integra battle on | PDF (68 KB)
p450 | doi:10.1038/nrd1767
Patent primer
Inherent anticipation | PDF (59 KB)
p451 | doi:10.1038/nrd1757
An Audience With
Jan M. Lundberg | PDF (87 KB)
p452 | doi:10.1038/nrd1764
From the analyst's couch
Future of COX2 inhibitors | PDF (217 KB)
p453 | doi:10.1038/nrd1755
Fresh from the Pipeline
Pregabalin | PDF (138 KB)
p455 | doi:10.1038/nrd1756
Research Highlights
Antithrombotic drugs: Sheer inhibition | PDF (146 KB)
p457 | doi:10.1038/nrd1771
HIV-1: Strategic targeting of the host | PDF (404 KB)
p458 | doi:10.1038/nrd1760
Diabetes and obesity: Battling the bulge with AGF | PDF (188 KB)
p458 | doi:10.1038/nrd1763
Gene expression: Do microarrays match up? | PDF (294 KB)
p459 | doi:10.1038/nrd1761
Computational chemistry: A stitch in time... | PDF (150 KB)
p460 | doi:10.1038/nrd1759
In brief
Antibacterial drugs | G-protein-coupled receptors | Computational Chemistry | Alzheimer's disease | PDF (150 KB)
p460 | doi:10.1038/nrd1762
Perspectives
Innovation
Can cell systems biology rescue drug discovery?
Eugene C. Butcher
p461 | doi:10.1038/nrd1754
Opinion
A pathophysiological paradigm for the therapy of psychiatric disease
Michael Spedding, Thérèse Jay, Jorge Costa e Silva & Laurent Perret
p467 | doi:10.1038/nrd1753
Reviews
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
Danielle H. Dube & Carolyn R. Bertozzi
p477 | doi:10.1038/nrd1751
Idiosyncratic drug hepatotoxicity
Neil Kaplowitz
p489 | doi:10.1038/nrd1750
Measuring the value of pharmacogenomics
Kathryn A. Phillips & Stephanie L. Van Bebber
p500 | doi:10.1038/nrd1749
Case history
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab
Lawrence Steinman
p510 | doi:10.1038/nrd1752
Careers and Recruitment
Career focus
Biopharma in Piedmont, Italy
Kjell S. Sakariassen
p519 | doi:10.1038/nrd1769
